Starling Oncology, Inc. STLN
$6.90
$0.274.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 34.62% | 41.22% | 41.58% | 36.70% | 21.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.62% | 41.22% | 41.58% | 36.70% | 21.53% |
| Cost of Revenue | 31.10% | 42.42% | 39.19% | 37.54% | 19.58% |
| Gross Profit | 55.22% | 35.17% | 55.54% | 31.70% | 34.35% |
| SG&A Expenses | 11.28% | 11.18% | 12.80% | -5.24% | -3.46% |
| Depreciation & Amortization | 1.83% | -9.42% | -4.39% | 9.54% | 18.91% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.63% | 34.67% | 32.68% | 27.13% | 13.98% |
| Operating Income | 58.83% | 34.29% | 42.10% | 41.86% | 31.49% |
| Income Before Tax | 42.89% | 87.28% | 43.04% | -2.43% | -10.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.45% | 87.28% | 43.04% | -2.43% | -9.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.45% | 87.28% | 43.04% | -2.43% | -9.88% |
| EBIT | 58.83% | 34.29% | 42.10% | 41.86% | 31.49% |
| EBITDA | 70.47% | 39.74% | 48.40% | 48.44% | 36.64% |
| EPS Basic | 46.70% | 90.12% | 55.77% | 19.30% | 11.50% |
| Normalized Basic EPS | 48.30% | 88.26% | 57.91% | 20.63% | 11.00% |
| EPS Diluted | 46.70% | 90.19% | 56.10% | 21.50% | 11.71% |
| Normalized Diluted EPS | 48.30% | 88.26% | 57.91% | 20.63% | 11.00% |
| Average Basic Shares Outstanding | 10.54% | 32.04% | 34.10% | 29.06% | 24.69% |
| Average Diluted Shares Outstanding | 10.54% | 32.04% | 34.10% | 29.06% | 24.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |